Recent studies have shown that Wnt5a, a non-canonical Wnt ligand, activates the IDO1 pathway, thereby reinforcing immune suppression while sustaining metabolic adaptations that support tumor survival and proliferation (Holtzhausen et al., 2015; Zhao et al., 2018; DeVito et al., 2021). This evidence concerns the gene WNT5A and neoplasm.